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Objective: Managing critical limb ischemia (CLI) is challenging. Furthermore, ischemic myopathy prevents good functional
outcome after revascularization. Hence, we have focused on limiting the tissue damage rather than angiogenesis, which has
traditionally been the motivation to develop nonsurgical treatments for CLI. Erythropoietin (EPO) protects ischemic tissue,
and this property may also beneﬁt CLI. The objective of this study was to examine the expression of the tissue-protective EPO
receptor complex (EPOR-CD131 [b-chain of interleukin (IL)-3/IL-5/granulocyte macrophage colony-stimulating factor
receptor]) in skeletalmuscle obtained fromhumanswithCLI.Because nativeEPO is thrombogenic, the antiapoptotic and anti-
inﬂammatoryeffectsofanonhematopoietichelix-BpeptideofEPO(ARA290)were investigatedon ischemicmyotubes invitro.
Methods: Tissue was obtained from gastrocnemius muscle of 12 patients undergoing amputation for CLI and from 12
patients without limb ischemia. The expression of EPOR and CD131 was demonstrated by immunohistochemistry and
Western blot. A validated in vitro model of myotube ischemia was used in which mature C2C12 myotubes were cultured
6 to 12 hours in a depleted media and gas mixture (20% CO2 and 80% N2). The myotubes were pretreated with EPO or
ARA 290 before exposure to simulated ischemia. Apoptosis and cell death were determined by cleaved caspase-3 assay and
lactate dehydrogenase release assay. Enzyme-linked immunosorbent assay measured the inﬂammatory cytokines.
Results: EPORandCD131were expressed and signiﬁcantly upregulated inCLI (average optical density [OD] inWestern blot
[control vs CLI] EPOR, 0.05U vs 0.1U;CD131, 0.10U vs 0.22U; P < .01). There was colocalization of EPORandCD131
in the sarcolemma (cell membrane) of the skeletal myoﬁber. There was no difference in the distribution of colocalization
between the CLI and the normal muscle. The ischemic myotubes treated by ARA 290 in vitro had a signiﬁcantly decreased
number of apoptotic cells (ischemia vs ischemia plus ARA290: 71.1% vs 55.1%;P < .01), cleaved caspase-3 (ODof ischemia vs
ischemia plus ARA 290: 0.15 U vs 0.02 U; P < .01), lactate dehydrogenase release (ischemia vs ischemia plus ARA 290: 32.5
U/L vs 21.3 U/L; P < .01), and IL-6 release (OD at 450 nm, ischemia vs ischemia plus ARA 290: 0.18 vs 0.13; P < .01).
Conclusions: This study demonstrates the expression and the upregulation of EPOR and CD131 in CLI and also shows
that EPOR and CDI are colocalized in the cell membrane of both ischemic and control muscle ﬁber. The in vitro
experiments demonstrate that ARA 290 decreases inﬂammation and apoptosis of ischemic myotubes. ARA 290 may
potentially be used as adjunctive treatment for CLI. (J Vasc Surg 2014;60:191-201.)
Clinical Relevance: The upregulation of tissue-protective receptor complex of erythropoietin (EPO) in critical limb
ischemia (CLI) shows that, theoretically, it is possible to use EPO in CLI for tissue protection. Because EPO is
thrombogenic in its native form, we have shown that nonhematopoietic EPO derivatives are equally effective in decreasing
myotube cell death and inﬂammation in cell culture. These laboratory data may translate into an in vivo study and
potentially provide an alternate adjunctive treatment for CLI.Critical limb ischemia (CLI) is amajor cause ofmorbidity Alternative forms of treatment include pharmacotherapy,
andmortality. Conventional treatment involves endovascular
or surgical revascularization, or both. However, 25% of
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192 Joshi et al July 2014myopathy that is difﬁcult to reverse and, indeed, may worsen
after revascularization.3 The mitochondrial function as
energy, free oxygen radical, and apoptosis regulator is ﬂawed.
This creates a progressive deterioration in muscle perfor-
mance. Reduced antioxidant defenses further increase
apoptosis of the skeletal muscle cells.4,5 We have therefore
considered the possibility of decreasing apoptosis and inﬂam-
mation of ischemic skeletal muscle as an alternative adjunc-
tive treatment for CLI.
Erythropoietin (EPO) provides ischemic protection to
various tissues, including the brain and the myocardium,
and also helps in the functional and histologic recovery of
skeletal muscle subjected to mechanical trauma.6 Although
EPO receptors are primarily found in hematopoietic tissue,
their ubiquitous expression has been identiﬁed in most
tissues, including the skeletal muscle.7
However, EPO promotes erythropoiesis and augments
endothelial activation and platelet reactivity.8 This can
adversely affect patients at cardiovascular risk, due to
EPO’s increased thrombogenic potential. To overcome
this problem, nonhematopoietic receptor subtype-speciﬁc
ligands of EPO have been synthesized that can allow
higher effective doses of EPO to be administered without
causing hemopoiesis.9 These include carbamylated EPO,
asialo EPO, and the pyroglutamate helix-B surface peptide
of EPO (ARA 290).10
The parent EPO molecule has four helices: A, B, C,
and D. The hydrophilic helix B is responsible for binding
to the tissue-protective heteroreceptor complex of EPO
that contains two subunits of EPO receptor (EPOR) and
two subunits of CD131 (b-chain of interleukin [IL]-3/
IL-5/granulocyte macrophage colony-stimulating factor
receptor).11,12 This initiates downstream pathways that
regulate apoptosis and inﬂammation. ARA 290 is essen-
tially an engineered, low-molecular-weight linear peptide
of the helix B that binds to EPOR-CD131 but not
EPOR in isolation.13 When EPO binds to EPOR in isola-
tion, it causes hematopoiesis. However, when EPO or ARA
290 binds to EPOR-CD131, the result is tissue protection
without hematopoiesis.11
There is a local increase in EPOR and CD131 in the
tissues as a result of stress (ischemia, trauma, or burns)
and an increase in the concentration of proinﬂammatory
cytokines, including tumor necrosis factor-a (TNF-a),
which cause cell death.13 Endogenous or exogenously
administered EPO or ARA 290 can counteract the effects
of TNF-a and tip the balance in favor of cell recovery.
Hence, we believe that expression of EPOR and CD131
may be increased in CLI and that exogenous administra-
tion of ARA 290 may beneﬁt CLI patients. The expression
of EPOR in healthy human skeletal muscle has been shown
previously,14 but the expression of CD131 and its colocal-
ization with EPOR in human skeletal muscle have not been
shown so far. Additionally, there is no study that compares
the expression of these receptors in ischemic vs healthy
human skeletal muscle.
The hypotheses of this study are: First, there is expres-
sion and colocalization of EPOR and CD131 in humanskeletal muscle. Second, there is upregulation of EPOR
and CD131 in CLI. Third, ARA 290 decreases apoptosis
and inﬂammation in an in vitro model of myotube
ischemia.METHODS
This study was approved by the Royal Free Hospital,
London and Hertfordshire Research Ethics Committees.
Skeletal muscle biopsy. Gastrocnemius skeletal
muscle biopsies were obtained from 12 patients with CLI
undergoing perigenicular amputation and 12 patients
with no clinical evidence of peripheral arterial disease
undergoing great saphenous vein harvesting for coronary
artery bypass grafting. The ankle-brachial pressure index
was measured in all controls, and any patient with an ankle-
brachial pressure index of <0.9 was excluded from the
study. CLI was deﬁned as the presence of two of the
following criteria as recommended by the TransAtlantic
Inter-Society Consensus15: ischemic rest pain, ulceration or
gangrene of foot or toes, or ankle systolic blood pressure
of <50 mm Hg. The CLI group consisted of patients
undergoing major lower limb amputations for unrecon-
structable CLI.
During surgery, a separate incision was used for the
gastrocnemius muscle biopsy before amputation. In the
control group, the muscle biopsy was carried out from
the incision used for vein harvesting. Patients who under-
went major lower limb amputations for pathology other
than CLI (eg neuropathic nonhealing ulcers and trauma)
were excluded. Other exclusion factors common to both
groups were patients with chronic renal failure being
treated with EPO for anemia, other lower limb pathology,
clotting disorders, previous or current malignancy, or
inability or unwillingness to provide informed consent.
Patients’ characteristics and a comparison of major cardio-
vascular risk factors between the two groups are summa-
rized in the Table.
Immunohistochemistry. Parafﬁn-embedded 3-mm
skeletal muscle sections were used. Human tonsil tissue
was used as a positive control for staining EPOR, as
described before.16 Dewaxing was performed through
serial immersions in xylene and ethyl alcohol. The tissue
sections were preincubated in a solution of hydrogen
peroxide (10 mL) in methanol (500 mL), followed by 10%
normal goat serum for 20 minutes to block nonspeciﬁc
background staining. Primary antibodies, positive controls,
corresponding immunoglobulin G isotype-negative con-
trols, and biotinylated secondary antibodies were added, as
listed in the Supplementary Table (online only). A drop of
biotinylated avidin and a drop of horseradish peroxidase
(HRP) solution A and B respectively of Vectastatin ABC
Universal Elite kit (Vector Laboratories Inc, Burlingame,
Calif) were added to phosphate-buffered saline (PBS;
2.5 mL). The mixture was allowed to stand for 15 minutes
before being used to incubate the tissue sections at room
temperature for 20 minutes. The sections were washed with
PBS for 5 minutes.
Table. Patient characteristics and demographic proﬁle of
patients undergoing skeletal muscle biopsy
Variablea Control (n ¼ 12) CLI (n ¼ 12) P
Age, years 67.17 6 9.2 70.02 6 5.7 >.05b
ABPI 0.945 6 0.07 0.205 6 0.13 <.01b
Sex >.05c
Male 9 8
Female 3 4
Diabetes mellitus 4 5 >.05c
Hypertension 8 9 >.05c
Cigarette smoking 6 8 >.05c
Hypercholesterolemia 9 9 >.05c
Statin therapy 10 8 >.05c
Aspirin therapy 10 11 >.05c
ABPI, Ankle-brachial pressure index; CLI, critical limb ischemia.
aCategoric data are presented as numbers and continuous data as mean 6
standard deviation.
bUnpaired t-test.
cc2 test.
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1 drop of 3,30-diaminobenzidine, 1 drop of H2O2 [3,30-
diaminobenzidine substrate kit for peroxidase]; Vector
Laboratories Inc) was added for a maximum of 10 minutes.
Cell nuclei were counterstained for 5 minutes in Meyer’s
hematoxylin, followed by a wash in running water. The
slides were dipped once in acid alcohol, followed by
multiple immersions in bluing solution, and then washed
in running water. The sections were dehydrated by sequen-
tial immersion in ethyl alcohol and xylene and then left to
dry for 2 to 3 minutes to avoid air bubbles. Fixation and
mounting was performed using permanent Vecta Mount
H-500 mounting medium (Vector Laboratories Inc).
The images were viewed and photographed using an Axio-
skop 2 microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany).
Western blot of tissue samples and cell lysates. Skel-
etal muscle tissue was homogenized in lysis buffer (1 mM
ethylenediaminetetraacetic acid, 0.1% sodium dodecyl
sulfate, 0.5% sodium deoxycholate, 1% Triton, 1 mM phe-
nylmethylsulfonyl ﬂuoride, 1 mM NaF, 1 mM Na orthova-
nadate, 1mg/mL aprotinin, 5mg/mL leupeptin, and 5mg/
mL pepstatin). The samples were centrifuged at 10,000g for
5 minutes, and the supernatant was separated from the
pellet. Protein concentrations of the supernatant samples
were determined using the bicinchoninic acid protein assay
(Pierce Proteins, Northumberland, UK). Laemmli buffer
(2) was used to dilute the supernatant and obtain an equal
protein concentration in all of the samples. The supernatant
was collected and stored at 80C. To obtain the cell
lysates, the myotube (muscle cell) monolayer was harvested
on ice, thoroughly washed with cold PBS, and lysed in 75-
mL radioimmunoprecipitation assay buffer 1 solution
(150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM
Tris, pH 8.0; Sigma-Aldrich, St. Louis, Mo).
After this, 75-mL Laemmli buffer was added to each
well of the 12-well culture plate. The monolayer wasscraped with a cell scraper and collected into an Eppendorf
tube using a syringe with a 23-gauge needle. Approxi-
mately 5 mL (2%-5%) of 2-mercaptoethanol was added to
the cell extract, which was then heated at 95C for
5 minutes to denature the proteins. Extracts were centri-
fuged at 1600g for 5 minutes at 4C. The supernatant
was collected and stored at 80C. Twelve microliters
of sample were loaded onto each of the wells of a 12%
Tris-glycine gel (Invitrogen, Paisley, UK) along with
a broad-range protein marker.
The chamber was connected to the electric source,
and electrolysis was initiated at 125 volts for 1.5 to 2
hours. The proteins were transferred to the nitrocellulose
membrane (Hybond-C extra; Amersham Pharmacia Bio-
tech, Chalfont, Buckinghamshire, UK), by repeating the
electrolysis at 30 volts for 90 minutes. After transfer of
the proteins, the membranes were blocked in PBS-tween
with 5% milk for 2 hours. The membranes were incubated
overnight at 4C with speciﬁc antibodies as described in the
Supplementary Table (online only) for tissue samples. The
positive controls that were used were Jurkat cell whole-cell
lysates (sc-226; Santa Cruz Biotechnology, Santa Cruz,
Calif) for EPOR and HuT78 whole-cell lysates (sc-676;
Santa Cruz Biotechnology) for CD131. Jurkat cells are ob-
tained from a human T-cell lymphoid line that expresses
EPOR.17 HuT78 is a myeloid leukemic cell line18 that
expresses CD13119 and was recommended by the manufac-
turer of the antibody (sc-676; Santa Cruz Biotechnology).
For cell lysates, cleaved caspase-3 (Asp175) antibody
(Cell Signaling Technology Inc) was used. a-Tubulin anti-
body was used as loading control (ab4074; Abcam, Cam-
bridge, Mass).
The membranes were later washed and incubated with
appropriate horseradish peroxidase-linked secondary anti-
body at room temperature for 1 hour, as indicated in the
Supplementary Table (online only). The membrane was
developed using chemiluminescent substrate (Amersham
Pharmacia Biotech, Piscataway, NJ), and the blots were
developed against Hyperﬁlm ECL photographic ﬁlm
(Amersham Pharmacia Biotech). Band intensities were
determined by densitometry usingBiospectrumAC imaging
system (UVP, Upland, Calif).
Double immunoﬂuorescence colocalization of EPOR
and CD131. Immunoﬂuorescence double labeling was
performed to demonstrate the presence of the tissue-
protective heteroreceptor complex in the skeletal muscle.
Frozen sections were ﬁxed in ice-cold acetone, washed, and
then treated with 10% normal serum corresponding to the
species in which the secondary antibody is prepared, as
shown in the Supplementary Table (online only). For
double labeling, EPOR and CD131 antibodies (prepared
in different species) were mixed and used for incubation
at the same time (Supplementary Table, online only). Over-
night incubation at 4C was performed. The ﬂuorescent-
labeled secondary antibodies (Supplementary Table, online
only) were mixed and incubated for 30 minutes in the
dark. The residue was washed away with PBS. The cover
slips were mounted on the sections using VECTASHIELD
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(DAPI), which also acts as the blue counterstain for the
nuclear DNA. The images were viewed and saved using an
Axioscop 2 ﬂuorescence microscope.
Cell culture and incubation procedure. Differenti-
ated C2C12 myoblasts (myotubes) were used for the
in vitro experiments. The multinucleated C2C12 myotubes
have ultrastructure and contractile muscle cell features that
are very similar to adult skeletal muscle cell.20,21 Being an
inﬁnite cell line, it is also free from contaminating cells
found in human muscle cell primary culture. Commercially
available human muscle cells are expensive, have a ﬁnite life
span, and require special medium that is not amenable to
serum alterations to facilitate ischemic simulation. In our
experience, it is much easier to replicate the experiments
and obtain consistent results with C2C12 myotubes.
The expression of EPOR and CD131 is present in
ischemic and normal C2C12 myotubes on immunoﬂuores-
cence, a part of which we have already demonstrated previ-
ously.22 The differential expression in normoxia and
hypoxia was not quantiﬁed. However, a recent study has
demonstrated increased EPOR and CD131 expression in
kidney cells in response to ischemia-reperfusion injury.23
Fig 1 demonstrates the morphology of C2C12
myoblasts, myotubes (A) and the expression of EPOR
and CD131 in mature myotubes (B and C). The cell line
was obtained from the European Collection of Cell
Cultures (ECACC No. 91031101, passage 13; Salisbury,
UK). The myoblasts were grown in Dulbecco Modiﬁed
Eagle’s Medium (1, liquid, high glucose; Invitrogen
Ltd, Paisley, UK). The culture medium was supplemented
with 10% fetal calf serum (GIBCO, Paisley, UK), 100 U/
mL penicillin, and 100 g/mL streptomycin. Incubation
was performed in a humidiﬁed atmosphere of 21% O2,
74% N2, and 5% CO2 at 37C. The myoblasts were grown
in a T75 cell culture ﬂask (BD Falcon, Franklin Lakes, NJ)
containing 25 mL culture medium. The media was
changed every 48 hours. Myoblasts were cultured to
a maximum of 50% conﬂuence at this stage to avoid
contact inhibition of mitosis.
Cells between three and 12 passages were used.
C2C12 cells are very robust; however; in our experience,
it takes longer for them to grow if they are less than three
passages old, and they struggle to differentiate into myo-
tubes after serum deprivation if they are >12 passages
old. After trypsinization and resuspension of adherent cells,
cell density was assessed by a hemocytometer. A seeding
density between 10,000 and 50,000 cells/mL of culture
media was used for plating the culture dish for experiments.
Myoblasts were then cultured to 80% conﬂuence, after
which fetal calf serum was replaced with 2% heat-
inactivated horse serum to prevent myoblasts from dividing
further and to ensure maturation into myotubes. The
culture media were changed daily until the myotubes
appeared to be fully mature. A monolayer of multinucleated
myotubes is usually formed by the end of the week. In addi-
tion to changes in morphology, increased expression of
myogenin conﬁrmed differentiation into myoblasts.22Simulated ischemia. We used an in vitro model to
simulate ischemia of myotubes, as described previously.22
Brieﬂy, myotubes in a 24-hour-old culture media were
exposed to 20% CO2 and 80% N2 (British Oxygen Co Ltd,
Luton, UK) in hypoxic chambers (Modular Incubator
Chamber, MIC-101, Billups-Rothenberg Inc, Del Mar,
Calif). The chamber was ﬂushed with gas at 10 L/min for
20 minutes, sealed, and placed in an incubator at 37C for
8 hours. Control myotubes were maintained under nor-
moxic conditions (21% O2 plus 5% CO2) for equivalent
periods of time with standard culture media changes. After
8 hours, the supernatant and the cell lysates were collected
from the culture dishes for enzyme-linked immunosorbent
assay (ELISA) and Western blot analysis, respectively.
Pretreatment with EPO and ARA 290. Myotubes
were pretreated with ARA 290 (Araim Pharmaceuticals
Inc, Ossining NY) or recombinant human EPO (rhEPO,
hBA-165: sc-4620; Santa Cruz Biotechnology Inc) or
24 hours before exposure to simulated ischemia. The
timing of pretreatment and the dose of rHuEPO (60 ng/
mL of culture media) was based on our previous study.22
For ARA 290, the manufacturer, based on its experi-
ments on anterior horn brain cells, recommended a dose
range of 2.5 to 6.3 ng/mL of culture media.24 We pre-
treated myotubes to ARA 290 with doses varying from
1 ng/mL to 10 mg/mL. On the dose-response curve, the
dose responsible for the least number of apoptotic cells was
considered optimum.
Nuclear staining. DAPI binds with the nuclear DNA.
Normal nuclei stain homogenously, whereas apoptotic
nuclei can be differentiated by the condensed chromatin
accumulating at the fringes of the nuclear membrane or
a total fragmented phenotype of the nuclei. Myotube
monolayers on culture slides were ﬁxed with 4% formalin
solution. Fluorescent nuclear staining to detect apoptotic
myotube nuclei was performed using VECTASHIELD
Mounting Medium containing DAPI. The morphology
was observed using an Axioskop 2 ﬂuorescence microscope
at an excitation wavelength of 350 nm.
For quantiﬁcation, two blinded observers counted
a minimum of three randomly chosen ﬁelds, of at least
three independent experiments, per experimental condi-
tion. At least 250 individual nuclei were counted at one
time. Data were expressed as percentage of apoptotic cells
and statistically analyzed for signiﬁcant difference between
those with and without rhEPO or ARA 290 pretreatment.
Lactate dehydrogenase assay. Lactate dehydrogenase
(LDH) is a marker of cell death. The assay was performed
according to themanufacturer’s protocol. A fully automated
Cytotoxicity Detection kit (LDH) from Roche/Hitachi
(Mannheim, Germany) was used to measure LDH release
in units per liter in culture media obtained from myotubes
subjected to simulated ischemia. The release of LDH into
the culture medium was assayed by incubating the clariﬁed
culture medium with sodium pyruvate in the presence of
nicotinamide adenine dinucleotide (NAD) phosphate
hydrogen (NADH). Pyruvic acid is catalyzed into lactic
acid by free LDH along with a simultaneous oxidation of
Fig 1. The expression of erythropoietin receptor complex (EPOR) and b-chain of interleukin (IL)-3/IL-5/gran-
ulocyte macrophage colony-stimulating factor receptor (CD131) in C2C12 myotubes. Representative photomicro-
graphs of C2C12 cells. A, Hematoxylin and eosin staining of myoblasts and mature multinucleated myotubes. B,
Expression of EPOR in myotubes (ab10653) using immunoﬂuorescence. C, Expression of CD131 in myotubes using
immunoﬂuorescence. The arrows represent the expression along the myotubes. The nuclei were stained with
4,06-diamidino-2-phenylindole. Anti-EPOR antibody (ab10653) and anti-CD131 antibody (DM3566P) was used for
showing the expression of EPOR and CD131, respectively. Texas-Red ﬂuorescent dye (Alexa Fluor 594; Alexa Fluor,
Paisley, UK) was used. Original magniﬁcation 40.
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NADþ was measured spectrophotometrically at 340 nm.
ELISA analysis. The Mouse Inﬂammatory Cytokines
& Chemokines Multi-Analyte ELISArray Kit (SABiosci-
ences, Frederick, Md) was used to concurrently analyze a
panel of 12 proinﬂammatory cytokines using a conventional
ELISA protocol. The cytokines and chemokines represented
by this array were IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-10,
IL-12, IL-17 A, interferon-g, TNF-a, granulocyte colony-
stimulating factor, and granulocyte macrophage colony-
stimulating factor.
The procedure was performed according to the manu-
facturer’s protocol. Replicate serial dilutions of the antigenstandard and supernatant from the myotube culture were
prepared. A total of 50-mL assay buffer and 50-mL samples
or standards were transferred to the appropriate wells of the
ELISA strips. The plate was gently agitated for 10 seconds
and incubated for 2 hours at room temperature. The well
contents were aspirated and washed thrice with 350-mL
1 washing buffer, after which 100-mL detection antibody
solution was added and incubated for 1 hour at room
temperature. After washing, 100-mL Avidin-HRP solution
was added to all of the wells and incubated for 30 minutes
at room temperature and then washed. One hundred
microliter development solution was added to each well,
and the plate was incubated for 15 minutes at room
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tion was added to each well. HRP cleaves the substrate
molecule tetramethylbenzidine, which is yellow in color.
An ELISA plate reader at a wavelength of 450 nm
measured the optical density (OD) or absorbance of the
yellow light of this substrate #30 minutes of stopping
the reaction. The wavelength of absorbance depends on
the color of the substrate used.
Statistics. The sample size chosen was based on calcu-
lations from pilot data obtained using preliminary validation
and optimization studies. The objective was to detect
a difference in the expression of EPOR andCD131 between
the CLI group and the appropriate controls. The outcome
measure was the relative density of the protein band ob-
tained through chemiluminescence in the Western blot.
We determined from the median values and interquar-
tile range of preliminary study and published data for
EPOR density that at least 12 patients per group gave
>90% power to detect a threefold difference in expression
of EPOR at a 5% signiﬁcance level. If the study were pow-
ered for a 50% increase, there would have been an increase
in the number of patients needed in each group. However,
this would have adversely affected the time and resources
needed to accomplish the study.
The experiments were performed in triplicate and
repeated at least three times, where appropriate. For quanti-
tative variables, comparison was made between the mean 6
standard deviation of triplicate samples from the same exper-
iment and from combined independent experiments when
interexperiment variation allowed a reliable combination of
raw data. To ensure that the combination of raw data was
reliable to perform, experiments on the tissue lysate from
the same patient were performed in one sitting, using similar
protein loading and exposure time during development.
The two-tailed Student t-test was used to compare
parametric data from two sets of independent samples,
and one-way analysis of variance/Tukey honestly signiﬁ-
cant difference test was used to compare parametric data
from more than two sets of independent samples. The c2
test was used for comparison of binomial nonparametric
data. Interobserver variability was measured using linear
correlation by calculating the Pearson product-moment
correlation coefﬁcient (r). P < .05 was considered signiﬁ-
cant. The data were analyzed using open-access online
statistical computation software (http://faculty.vassar.
edu/lowry/VassarStats.html).
RESULTS
Immunologic expression of EPOR in human skel-
etal muscle and its upregulation in CLI. EPOR immu-
noreactivity was demonstrated in human skeletal muscle
using immunohistochemistry and Western blot. EPOR
expression was present mainly in the sarcolemma of the
myoﬁbrils in normal control muscle; however, the distribu-
tion was more generalized in CLI (Fig 2, A). On Western
blot, a dominant band was obtained in the region of EPOR
(59 kDa) using ab10653 (Fig 2, A). By using the OD
technique, a signiﬁcant upregulation was measured in theexpression of EPOR in CLI, with an average OD of 0.05 U
for control vs 0.1U forCLI (P< .01). Fig 2,A demonstrates
the entire blot, which also shows nonspeciﬁc protein bands
obtained at 155 kDa, most probably from cross-reactivity.
Immunologic expression of CD131 in human
skeletal muscle and its upregulation in CLI. CD131
immunoreactivity was present in human skeletal muscle,
as demonstrated by immunohistochemistry (Fig 2, B).
The site of expression in CLI and control was similar to
EPOR. The expression of CD131 was conﬁrmed on
Western blot in the region of 130 kDa. CD131 was
signiﬁcantly upregulated in CLI (average OD: 0.1 U for
control vs 0.22 U for CLI; P < .01; Fig 2, B).
EPOR and CD131 are colocalized in human skel-
etal muscle. Thedouble immunoﬂuorescencedemonstrated
colocalization of EPOR and CD131. The colocalization
occurred along the peripherally located nuclei of the muscle
ﬁber, which are located along the cell membrane in the
periphery. This suggests that the colocalization was most
prominent in the sarcolemma (cell membrane) of the myo-
ﬁber (Fig 2, C). The colocalization was present in both
ischemic and control muscle. There was, however, no differ-
ence in the site of colocalization between normal muscle and
CLI.
ARA 290 pretreatment decreases apoptotic nuclear
fragmentation of ischemic myotubes in vitro. The dose-
response curve showed that the optimum dose of ARA 290
to decrease the maximum number of apoptotic cells was
8 ng/mL of culture media (Fig 3, A). The expected
optimum dose was slightly higher than that recommended
by the manufacturer (2.5 to 6.3 ng/mL), which had per-
formed its study on brain cells.24 There was a signiﬁcant
decrease in the number of fragmented nuclei in ischemic
myotubes pretreated with ARA 290 (71.1% for ischemia vs
55.1% for ischemia plus ARA 290; P < .01), as shown in
Fig 3, B. There was no interobserver variability between the
observations for the number of apoptotic cells made by two
independent blinded observers (Pearson product-moment
correlation coefﬁcient, r ¼ 0.997; n ¼ 45; data not shown).
ARA 290 pretreatment decreases cleaved caspase-3
expression in ischemic myotubes in vitro. Fig 3, C
shows a Western blot in which cleaved caspase-3, a marker
of apoptosis, was signiﬁcantly decreased when ischemic
myotubes were pretreated with ARA 290 at 8 ng/mL of
culture media (OD 0.15 U for ischemia vs 0.02 U for
ischemia plus ARA 290; P < .01).
ARA 290 decreases cell death-induced LDH release
from ischemic myotubes in vitro. There was a signiﬁcant
decrease in ischemia-induced LDH release from myotubes
pretreated with ARA 290 (32.5 U/L for ischemia vs 21.3
U/L for ischemia plus ARA 290; P < .01) as demonstrated
in Fig 4, A.
ARA 290 decreases IL-6 release from ischemic
myotubes in vitro. Although an array of inﬂammatory
cytokines was probed in the supernatant obtained after
ischemic treatment of myotubes, only IL-6 was found
within the measurable range. There was a signiﬁcant
decrease in IL-6 release from the ischemic myotubes
Fig 2. The expression of erythropoietin receptor complex (EPOR) and b-chain of interleukin (IL)-3/IL-5/gran-
ulocyte macrophage colony-stimulating factor receptor (CD131) and its upregulation in human critical limb ischemia
(CLI). Representative photomicrographs show human skeletal muscle sections. A, EPOR immunoreactivity is
demonstrated by immunohistochemistry. EPOR is expressed predominantly in the sarcolemma (s) of the control
myoﬁber (m); however, a more generalized EPOR expression is present in CLI. The Western blot shows EPOR
expression at 59 kDa and its signiﬁcant upregulation in CLI. B, CD131 immunoreactivity is demonstrated by
immunohistochemistry. Western blot shows CD131 expression at 130 kDa and its signiﬁcant upregulation in CLI. C,
EPOR and CD131 immunoﬂuorescent colocalization is demonstrated in the periphery and close to the nucleus (n) of
representative ischemic myoﬁber (m). This suggests predominant colocalization in the sarcolemma. The nuclei are
stained with 4,06-diamidino-2-phenylindole (DAPI). The arrow represents a site of expression or colocalization. Anti-
EPOR antibody (ab10653) was used in immunohistochemistry and Western blot; Jurkat and HuT 78 whole cell lysates
were used as positive controls for EPOR and CD131, respectively. b-Actin was used as the loading control in Western
blot. Anti-EPOR antibody (Ww12) and anti-CD131 antibody (N-20) were used for immunoﬂuorescence colocali-
zation. Data are represented by mean 6 standard deviation (error bars); n ¼ 12 for CLI and n ¼ 12 for control. Two-
tailed t-test for independent samples was used for analyses. IgG, Immunoglobulin G; PBS, phosphate-buffered saline.
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Fig 3. Pretreatment with nonhematopoietic helix-B peptide of erythropoietin (ARA 290) decreases apoptotic nuclear
fragmentation and cleaved caspase-3 release in ischemic myotubes in vitro. A, The dose-response curve shows that ARA
290 at 8 ng/mL of culture media was the optimum dose to decrease the maximum number of apoptotic cells. B,
Representative ﬂuorescent (grayscale) photomicrographs show increased bright 4,06-diamidino-2-phenylindole-stained
apoptotic nuclei in the ischemic myotubes compared with control normoxic myotubes. The number of apoptotic nuclei
was signiﬁcantly reduced when myotubes were pretreated with ARA 290 before ischemic exposure. C, Representative
Western blot of cleaved caspase-3 assay demonstrates signiﬁcantly decreased cleaved caspase-3 expression in the cell
lysates obtained from C2C12 myotubes exposed to simulated ischemia but pretreated with ARA 290. Jurkat cells
treated with cytochrome C were used as positive controls, and myotubes incubated in normoxia were used as positive
controls. All data are represented by mean 6 standard deviation (error bars), n ¼ 9. Two-way analysis of variance/
Tukey honestly signiﬁcant differences test was used. EPO, Erythropoietin.
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0.13 U; P < .01; Fig 4, B).
DISCUSSION
In this study, the expression of EPO receptors within
human skeletal muscle and their elevated expression inCLI have been demonstrated. Additionally, we have shown
that there is colocalization of EPOR and CD131 in the
sarcolemma. This suggests that the tissue-protective receptor
complex of EPO is present in skeletal muscle. We have also
shown that ARA 290 decreases inﬂammation and apoptosis
of ischemic myotubes in vitro.
AB
Fig 4. Nonhematopoietic helix-B peptide of erythropoietin (ARA 290) pretreatment decreases lactate dehydrogenase
(LDH) and interleukin (IL)-6 release from ischemic myotubes in vitro. A, ARA 290 and erythropoietin (EPO)
signiﬁcantly decreased the total LDH released from myotubes (measured as units per liter of media by calorimetry). B,
Enzyme-linked immunosorbent assay results show that EPO and ARA 290 signiﬁcantly attenuated the release of IL-6
measured in the culture media of C2C12 myotubes after exposure to ischemic simulation. Negative control immu-
noglobin A (IgG A) and positive controls were antibody speciﬁc and provided by the manufacturer in the enzyme-
linked immunosorbent assay kit. All data are represented by mean 6 standard deviation (error bars), n ¼ 9.
Two-way analysis of variance/Tukey honestly signiﬁcant differences test was used.
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skeletal muscle has been previously shown, the upregula-
tion of EPOR in CLI has been shown for the ﬁrst time.
The expression of EPOR in nonischemic human skeletal
muscle was more pronounced in the sarcolemma of healthy
myoﬁbrils. This ﬁnding was consistent with the results ob-
tained by Lundby et al14 and Rundqvist et al.25 However in
CLI, the immunoreactivity was not limited to the sarco-
lemma but was also present in the intracellular location
(Fig 2, A). Brines et al13 showed that EPO receptors
increase as a protective response to ischemic insult. Hence,
it is possible that the generalized EPOR expression may
occur due to increased intracellular EPO receptor produc-
tion, before they are added to the membrane.There have been concerns regarding the speciﬁcity of
EPOR antibodies. Some EPOR antibodies display a domi-
nant protein band at approximately 70 kDa, which in fact is
the molecular weight of heat shock proteins.26 Using
ab10653, we were able to show expression of EPOR at
59 kDa, which is considered the true expression of
EPOR.26
There is no previous evidence for the presence of
CD131 in skeletal muscle. However, CD131 is a class 1
cytokine receptor found ubiquitously in most tissues.
Hence, it was expected to be present in the skeletal muscle.
CD131 colocalization with EPOR has previously been
shown only in spinal cord neurons and cardiomyocytes.12
A wide variation was noted in the site of colocalization
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peripheral to more diffuse. The colocalization of EPOR
and CD131 in skeletal muscle myoﬁber in our study was
present in the region of sarcolemma, as suggested by the
expression along the peripherally situated nuclei. There
was no difference in the colocalization between ischemic
and control muscle in our study, which may indicate that
colocalization and, hence, the EPOR-CD131 heterorecep-
tor complex, is limited to the cell membrane.
The tissue-protective effects of EPO are secondary to
inhibition of apoptotic pathways and attenuation of inﬂam-
mation.27-29 Hence, for the second part of the study, we
used attenuation of ischemia-induced apoptosis and inﬂam-
mation to demonstrate the dose-dependent tissue-protec-
tive effects of ARA 290 in a cell culture model of mature
myotubes. This model aims to imitate the in vivo character-
istics of CLI rather than hypoxia alone. We acknowledge
that this model is designed to resemble some aspects of
CLI and not to recreate CLI. CLI is difﬁcult to replicate
in in vitro and in animal models. As a proof of concept,
we had demonstrated in our previous study, the antiapop-
totic properties of rhEPO on ischemic myotubes.22 In this
study, we used the model to test antiapoptotic properties of
ARA 290 and used rhEPO as a positive control. ARA 290
mirrored the antiapoptotic and anti-inﬂammatory effects of
rhEPO. This shows that ARA 290 is as effective as rhEPO
in vitro for limiting ischemic damage on myotubes in vitro.
Receptor-initiated cell signalling by EPO and ARA 290
to decrease apoptosis occurs via multiple molecular
cascades, which differ in importance depending on the
speciﬁc tissue or cell type, as well as the type of injury.13
As in erythropoiesis, most tissue-protective responses begin
by the phosphorylation of Janus kinase-2 or Janus kinase-
1.30,31 After Janus kinase-2 phosphorylation, three main
pathways are activated that result in attenuation of
apoptosis: signal transducers and activator of transcription
type 5/Bcl-xL32; phosphatidyl inositol-3 kinase/protein
kinase B (PI3K/Akt)33; and in some tissues, including
the heart, the mitogen-activated protein kinase (MAPK)
pathway is involved.34 MAPK and PI3K/Akt inhibit cas-
pase activation, which directly inhibits apoptosis. We have
shown that ARA 290 decreases cleaved caspase-3 in the
myotubes subjected to ischemia. This indicates that EPO
and ARA 290 may attenuate apoptosis through the
MAPK or PI3K/Akt pathway. This is consistent with
a recent study that demonstrated a peptide similar to
ARA 290 decreased apoptosis in response to ischemia-
reperfusion injury via the PI3K/Akt signaling pathway.23
We are not aware that ARA 290 binds to any other
receptor.
By using the Multi-Analyte ELISArray Kit to measure
the amount of inﬂammatory cytokines in the supernatant
of the cell culture, we found that IL-6 was the only inﬂam-
matory cytokine detected in measurable quantities in the
supernatant. This could be because we only used the super-
natant and not the cell lysate for ELISA. But, there is
evidence that skeletal muscle, including human and mouse
myoblasts, produce IL-6 in response to inﬂammatorystimuli.35,36 In fact, C2C12 myoblasts express a variety of
LPS- and cytokine-responsive messenger RNAs, including
IL-6, IL-1a, IL-1Ra, IL-12, TNF-a, and transforming
growth factor-b1, -b2, and -b3.
35 However, IL-6 is the
only cytokine that is expressed in substantial amounts,
which explains why IL-6 was predominantly detected in
our experiment. Furthermore, high levels of IL-6 are asso-
ciated with a reduction in muscle mass and muscle
strength, and IL-6 blockade can be protective in some
models of sepsis.37,38 We have shown that ARA 290 can
attenuate ischemia-induced IL-6 release in myotubes,
which may indicate the potential use of ARA 290 in
reducing ischemic tissue damage. However, further studies
are needed to assess the in vivo effects of ARA 290.
CONCLUSIONS
We have provided further evidence of the presence and
the colocalization of tissue-protective EPO heteroreceptor
complex (EPOR-CD131) within the human skeletal
muscle and its elevated expression in CLI. We have also
demonstrated that ARA 290, a nonhematopoietic peptide
of EPO, decreases inﬂammation and apoptosis of ischemic
myotubes in vitro. This may provide a novel therapeutic
avenue for adjunctive treatment of CLI.
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Supplementary Table (online only). Antibodies and controls used in immunohistochemistry (IHC), Western blot
(WB), and immunoﬂuorescence (IF)
Antibody Type Manufacturer Dilution Incubation time
IHC
Anti-EPOR Goat polyclonal Ab10653; Aabcam 1:100 Overnight, 4C
Anti-CD131 Rabbit polyclonal sc-676; Santa Cruz Biotechnology Inc 1:200 1 hour, room temp
WB
Anti-EPOR Goat polyclonal Ab10653; Abcam 1:1000 Overnight, 4C
Anti-CD131N-20 Rabbit polyclonal sc-676; Santa Cruz Biotechnology Inc 1:1000 Overnight, 4C
IF
Anti-EPOR (Ww12) Mouse monoclonal sc-80030; Santa Cruz Biotechnology Inc 1:100 Overnight, 4C
Anti-CD131N-20 Rabbit polyclonal sc-676; Santa Cruz Biotechnology Inc 1:100 Overnight, 4C
Anti-CD131DM3566P Rat monoclonal Acris antibodies 1:100 Overnight, 4C
CD131, b-chain of interleukin (IL)-3/IL-5/granulocyte macrophage colony-stimulating factor receptor; EPOR, erythropoietin receptor; HRP, horseradish
peroxidase; IgG, immunoglobulin G; NA, not applicable; PBS, phosphate-buffered saline.
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IgG isotype/ negative control Positive control Biotinylated secondary antibody
Goat IgG Human tonsil Donkey antigoat
Rabbit IgG NA Goat antirabbit
PBS Jurkat whole cell lysate Antigoat IgG HRP linked
PBS HuT 78 whole cell lysates Antirabbit IgG HRP-linked
Mouse IgG 2b NA Alexa Fluor 594 goat antimouse IgG Cat. No. A-11005 (red)
Rabbit IgG NA Alexa Fluor 488 chicken antirabbit IgG Cat. No. A-21442 (green)
IgG2 NA Goat polyclonal secondary antibody to rat IgG - H&L
(Alexa Fluor 594) (red)
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